Market Research Logo

Ophthalmic Therapeutic Drugs: Technologies and Global Markets

Ophthalmic Therapeutic Drugs: Technologies and Global Markets

The global ophthalmic therapeutic drug market was valued at $12.3 billion in 2014. This market is expected to reach $19 billion by 2019, with a compound annual growth rate (CAGR) of 9.1% from 2014 to 2019.

This report provides:
An overview of the global market for ophthalmic therapeutic drugs.
Analyses of global market trends, with data from 2013 and 2014, and projections of CAGRs through 2019.
Investigation of one of the most important market drivers, combination therapies.
Learn how healthcare awareness and emerging middle classes in countries such as India, China, Brazil and Russia are providing market opportunities.
Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development.
Analysis of these major players to help define the specific product strategies which they are employing.


SCOPE OF REPORT

This report on ophthalmic therapeutics drugs provides a brief description of the current status of the industry and recent developments. The report analyzes the market trends, and identifies key therapeutic and geographical challenges and rising opportunities in the developed and developing world. Finally, it will provide insights into new developments into ophthalmic therapeutics including novel biologics, formulations and the launch of biosimilars and generics.

CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE REPORT
SCOPE OF REPORT
INTENDED AUDIENCE
METHODOLOGY AND INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 SUMMARY
SUMMARY TABLE GLOBAL OPHTHALMIC THERAPEUTIC DRUG MARKET BY SEGMENT, THROUGH 2019 ($ MILLIONS)
SUMMARY FIGURE GLOBAL OPHTHALMIC THERAPEUTIC DRUG MARKET BY SEGMENT,2013-2019 ($ MILLIONS)
CHAPTER 3 RETINAL DISEASES: AGE-RELATED MACULAR DEGENERATION
RETINAL DISEASE
FIGURE 1 STRUCTURE OF THE EYE
AGE-RELATED MACULAR DEGENERATION (AMD)
FIGURE 2 AMD ADDRESSABLE PATIENT POPULATION (NUMBERS)
DISEASE SUBTYPES
Early AMD
Intermediate AMD
Late-Stage AMD
Dry AMD
Wet AMD
FIGURE 3 PHYSIOLOGICAL CHANGES IN WET AND DRY AMD
DIAGNOSIS RATE
CURRENT TREATMENT
TABLE 1 PRODUCTS APPROVED TO TREAT WET AMD
CURRENT MARKET SIZE
TABLE 2 GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG, THROUGH 2019 ($ MILLIONS)
TABLE 3 GLOBAL AMD SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
TABLE 4 GLOBAL AMD SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 ($ MILLIONS)
FIGURE 4 GLOBAL MARKET SHARE OF AMD APPROVED PRODUCTS BY COMPANY, 2014 (%)
MARKET DRIVERS
AREAS OF UNMET CLINICAL NEED
TABLE 5 AREAS OF UNMET CLINICAL NEED IN AMD TREATMENT
NEW THERAPIES FOR WET AMD
CONBERCEPT (CHENGDU KANGHONG PHARMACEUTICAL GROUP)
LAMPALIZUMAB (GENENTECH)
BROLUCIZUMAB (ALCON)
FOVISTA + ANTI-VEGF COMBINATION (ALCON/OPHTHOTECH)
TABLE 6 PRODUCTS IN DEVELOPMENT FOR WET AMD – PHASE III
TABLE 7 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE II
TABLE 8 PRODUCTS IN DEVELOPMENT FOR WET AMD - PHASE I
NEW TREATMENTS FOR DRY AMD
TABLE 9 PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE III
TABLE 10 PRODUCTS IN DEVELOPMENT FOR DRY AMD - PHASE II
NEW THERAPIES
Emixustat Hydrochloride (Acucela/Otsuka)
FIGURE 5 MECHANISM OF ACTION OF ACUCLEA'S VCMS
GSK-933776 (GSK)
FUTURE MARKET SIZE
TABLE 11 GLOBAL AMD SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
TABLE 12 GLOBAL AMD SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
SUMMARY
CHAPTER 4 GLAUCOMA
FIGURE 6 GLAUCOMA ADDRESSABLE PATIENT POPULATION (NUMBERS)
DISEASE SUBTYPES
PRIMARY OPEN-ANGLE GLAUCOMA
PRIMARY ANGLE-CLOSURE GLAUCOMA
FIGURE 7 SCHEMATIC OF OPEN AND CLOSED ANGLE GLAUCOMA
DIAGNOSIS RATE
CURRENT TREATMENT
TABLE 13 APPROVED GLAUCOMA DRUG CHARACTERISTICS
MONOTHERAPY
TABLE 14 PRODUCTS APPROVED TO TREAT GLAUCOMA - MONOTHERAPY
FIXED DOSE COMBINATIONS
TABLE 15 PRODUCTS APPROVED TO TREAT GLAUCOMA - FIXED DOSE
COMBINATIONS
Prescription Patterns
FIGURE 8 PRESCRIPTION DRUG CLASSES IN THE U.S., 2013 (%)
FIGURE 9 PRESCRIPTION DRUG CLASSES IN EUROPE, 2013 (%)
FIGURE 10 PRESCRIPTION DRUG CLASSES IN JAPAN, 2010 (%)
CURRENT MARKET SIZE
TABLE 16 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS, THROUGH 2019 ($ MILLIONS)
TABLE 17 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
FIGURE 11 GLOBAL MARKET SHARE OF GLAUCOMA APPROVED PRODUCTS BY DRUG CLASS, 2014 (%)
TABLE 18 GLOBAL GLAUCOMA SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 ($ MILLIONS)
FIGURE 12 GLOBAL MARKET SHARE OF GLAUCOMA APPROVED PRODUCTS BY COMPANY, 2014 (%)
MARKET DRIVERS
AREAS OF UNMET CLINICAL NEED
TABLE 19 AREAS OF UNMET CLINICAL NEED IN GLAUCOMA TREATMENT
NEW DELIVERY APPROACHES AND FORMULATIONS
TABLE 20 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE III
TABLE 21 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE II
TABLE 22 PRODUCTS IN DEVELOPMENT TO TREAT GLAUCOMA - PHASE I
NEW THERAPIES
RHO KINASE (ROCK) INHIBITORS
GLANATEC (KOWA)
RHOPRESSA AND ROCLATAN (AERIE PHARMACEUTICALS)
FIGURE 13 QUADRUPLE MODE OF ACTION OF AERIE PHARMACEUTICALS'
RHOPRESSA
TABLE 23 ROCK INHIBITORS IN DEVELOPMENT
GENE SILENCING AGENTS
TABLE 24 GENE SILENCING AGENTS IN DEVELOPMENT
BAMOSIRAN (SYLENTIS SA)
IST-0036 (ISARNA THERAPEUTICS GMBH)
QPI-1007 (QUARK PHARMACEUTICALS)
EARLY-STAGE DRUG DEVELOPMENT
ANTI-AMYLOID BETA AGENTS
CANNABINOIDS
TRANSIENT RECEPTOR POTENTIAL VANILLOID ISOFORM 4 (TRPV4)
FUTURE MARKET SIZE
TABLE 25 GLOBAL GLAUCOMA SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
TABLE 26 GLOBAL GLAUCOMA SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
SUMMARY
CHAPTER 5 DRY EYE SYNDROME
FIGURE 14 DRY EYE SYNDROME ADDRESSABLE PATIENT POPULATION (NUMBERS)
DIAGNOSIS RATE
CURRENT TREATMENT
TABLE 27 PRODUCTS APPROVED TO TREAT DES
CURRENT MARKET SIZE
TABLE 28 GLOBAL DES SALES OF APPROVED PRODUCTS, THROUGH 2019 ($ MILLIONS)
TABLE 29 GLOBAL DES SALES OF APPROVED PRODUCTS BY DRUG CLASS,
THROUGH 2019 ($ MILLIONS)
FIGURE 15 GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY DRUG CLASS, 2014 (%)
TABLE 30 GLOBAL DES SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 ($ MILLIONS)
FIGURE 16 GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY COMPANY, 2014 (%)
MARKET DRIVERS
AREAS OF UNMET CLINICAL NEED
TABLE 31 AREAS OF UNMET CLINICAL NEED IN DES TREATMENT
NEW THERAPIES
CYCLOKAT/IKERVIS (SANTEN PHARMACEUTICAL)
LIFITEGRAST (SHIRE)
REFRESH (ACTAVIS)
EBI-005 (ELEVEN BIOTHERAPEUTICS)
EGP-435 (EYEGATE PHARMA/VALEANT PHARMACEUTICALS)
MIM-D3 (MIMETOGEN)
TABLE 32 PRODUCTS IN DEVELOPMENT TO TREAT DES - PHASE III
TABLE 33 PRODUCTS IN DEVELOPMENT TO TREAT DES - PHASE II
NEW FORMULATIONS
EARLY-STAGE DRUG DEVELOPMENT
FUTURE MARKET SIZE
TABLE 34 GLOBAL DES SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
TABLE 35 GLOBAL DES SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
SUMMARY
CHAPTER 6 UVEITIS
FIGURE 17 UVEITIS ADDRESSABLE PATIENT POPULATION (NUMBERS)
DIAGNOSIS RATE
CURRENT TREATMENT
TABLE 36 PRODUCTS APPROVED TO TREAT UVEITIS
CURRENT MARKET SIZE
TABLE 37 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS, THROUGH 2019 ($ MILLIONS)
TABLE 38 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
FIGURE 18 GLOBAL MARKET SHARE OF UVEITIS APPROVED PRODUCTS BY DRUG CLASS, 2014 (%)
TABLE 39 GLOBAL UVEITIS SALES OF APPROVED PRODUCTS BY COMPANY, THROUGH 2019 ($ MILLIONS)
FIGURE 19 GLOBAL MARKET SHARE OF UVEITIS APPROVED PRODUCTS BY COMPANY, 2014 (%)
MARKET DRIVERS
AREAS OF UNMET CLINICAL NEED
TABLE 40 AREAS OF UNMET CLINICAL NEED IN UVEITIS TREATMENT
NEW THERAPIES
GEVOKIZUMAB (XOMA)
SIROLIMUS (SANTEN PHARMACEUTICAL)
TABLE 41 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE III
TABLE 42 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE II
TABLE 43 PRODUCTS IN DEVELOPMENT TO TREAT UVEITIS - PHASE I
NEW FORMULATIONS
EGP-437 (EYEGATE PHARMA/ VALENAT PHARMACUETICALS)
EARLY-STAGE DRUG DEVELOPMENT
FUTURE MARKET SIZE
TABLE 44 GLOBAL UVEITIS SALES OF PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
TABLE 45 GLOBAL UVEITIS SALES OF APPROVED AND PIPELINE PRODUCTS, THROUGH 2019 ($ MILLIONS)
SUMMARY
CHAPTER 7 RECENT MARKET ACTIVITY
ALLIANCES AND LICENSING DEALS
FIGURE 20 OPHTHALMIC ALLIANCE AND LICENSING DEALS BY YEAR, 2007-2014 (NO. OF DEALS)
FIGURE 21 OPHTHALMIC ALLIANCE AND LICENSING DEALS BY TERRITORY, 2007-2014 (NO. OF DEALS)
TABLE 46 LEADING OPHTHALMIC DEALS IN THE U.S. BASED ON VALUE, 2007-JULY 2015 ($ MILLIONS)
TABLE 47 LEADING OPHTHALMIC DEALS IN ASIA BASED ON VALUE, 2007-2014 ($ MILLIONS)
TABLE 48 LEADING OPHTHALMIC DEALS IN EUROPE BASED ON VALUE, 2007-2014 ($ MILLIONS)
ALLIANCES AND LICENSING DEALS BY THERAPEUTIC CATEGORY
FIGURE 22 OPHTHALMIC ALLIANCES AND LICENSING DEALS BY THERAPEUTIC CATEGORY, 2007-2014 (NO. OF DEALS)
TABLE 49 LEADING OPHTHALMIC DEALS IN AMD BASED ON VALUE, 2007-2014 ($ MILLIONS)
TABLE 50 LEADING OPHTHALMIC DEALS IN RETINOPATHY BASED ON VALUE, 2007-2014 ($ MILLIONS)
TABLE 51 LEADING OPHTHALMIC DEALS IN GLAUCOMA BASED ON VALUE, 2007-2014 ($ MILLIONS)
MERGERS AND ACQUISITIONS
FIGURE 23 OPHTHALMIC MERGERS AND ACQUISITIONS BY YEAR, 007-2014 (NUMBER)
TABLE 52 RECENT ACQUISITIONS IN THE OPHTHALMIC ARENA BASED ON VALUE, 2007- JULY 2015 ($ MILLIONS)
CHAPTER 8 COMPANY PROFILES
LEADING PHARMACEUTICALS COMPANIES
ACTAVIS (FORMERLY ALLERGAN)
ALCON
F. HOFFMANN-LA ROCHE
MERCK & CO.
SHIRE PLC
SUMITOMO DAINIPPON PHARMA
VALEANT PHARMACEUTICALS
LEADING SPECIALIST PHARMA COMPANIES
ACUCELA
AERIE PHARMACEUTICALS
INOTEK PHARMACEUTICALS
LUX BIOSCIENCES
MOLECULAR PARTNERS AG
OPTHERION PHARMACEUTICALS
PSIVIDA CORPORATION
REGENERON PHARMACEUTICALS
RESOLVYX PHARMACEUTICALS
SANTEN PHARMACEUTICAL CO. LTD
SYLENTIS S.A.
LEADING GENERIC AND BIOSIMILAR MANUFACTURER
AKORN INC.
CHAPTER 9 APPENDIX I: ACRONYMS
ACRONYMS
CHAPTER 10 APPENDIX II: REFERENCES
AMD REFERENCES
GLAUCOMA REFERENCES
DRY EYE SYNDROME REFERENCES
UVEITIS REFERENCES
WEBSITES
WEBLINKS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report